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Zusammenfassung
Eine besondere Herausforderung bei der Durchführung parenteraler
Ernährung (PE) bei pädiatrischen Patienten ergibt sich aus der großen
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alleFrühgeborenen<35.SSWundallekrankenReifgeborenenwährend
derPhasedesallmählichenAufbausderenteralenNahrungszufuhreine
vollständige oder partielle PE. Die Zufuhrmengen der PE bei Neonaten
müssen berechnet (nicht geschätzt) werden. Der Anteil der PE sollte
zurMinimierungvonNebenwirkungensobaldwiemöglichdurchEinfüh-
rung einer enteralen Ernährung vermindert (teilparenterale Ernährung)
und schließlich komplett durch enterale Ernährung abgelöst werden.
Eine unangemessene Substratzufuhr im frühen Säuglingsalter kann
langfristig nachteilige Auswirkungen im Sinne einer metabolischen
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Wenn bei älteren Kindern und Jugendlichen dagegen der Energie- und
NährstoffbedarfeinesPatientenimVorschul-oderSchulalterdurcheine
enterale Nährstoffzufuhr nicht gedeckt werden kann, ist abhängig von
Ernährungszustand und klinischen Umständen spätestens innerhalb
von 7 Tagen eine partielle oder totale PE zu erwägen.
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Preliminary remarks
The majority of recommendations on substrate intake
(withtheexceptionofthechapterson“Aminoacidrequire-
ments”and“Informationontheselectionandproduction
of amino acid solutions” in the attachment, which have
been specially drawn up for this set of guidelines) have
beendrawnupaccordingtothe“GuidelinesonPaediatric
Parenteral Nutrition”, a combined study group from the
EuropeanSocietyofPaediatricGastroenterology,Hepato-
logy and Nutrition (ESPGHAN, http://www. espghan.org)
and the European Society for Clinical Nutrition and
Metabolism (ESPEN, http://www.espen.org) [1]. System-
atic literature research has already been carried out for
the development of the European guidelines, therefore
further research for the current guidelines was unneces-
sary.
Introduction
Systematicreviewinanumberoffieldsproducedaseries
of published studies from which evidence-based recom-
mendations can be drawn up for the neonatal period
(1–28 days) and period of infancy (1–12 months). The
situation in children and teenagers is, however, different
with extremely limited data available from randomised
controlled clinical studies on children after the neonatal
period.
There is a special challenge in implementing parenteral
nutrition (PN) in paediatric patients, which arises from
the wide range of patients, ranging from extremely pre-
mature infants up to teenagers weighing up to and over
100 kg, and their varying substrate requirements. Age
andmaturity-relatedchangesofthemetabolismandfluid
and nutrient requirements must be taken into consider-
ation along with the clinical situation during which PN is
applied. The indication, the procedure as well as the in-
take of fluid and substrates are very different to that
knowninPN-practiceinadultpatientsTherefore,itmakes
sense to briefly present some of physiological features
of paediatric patients that are significant for PN in order
tounderstandthenutritionalstrategiesusedforchildren
and teenagers.
• The fluid, nutrient and energy intake of premature in-
fants and newborns is higher per kg body weight than
that of older paediatric and adult patients (II).
• The substrate requirements of paediatric patients
cannot be proportionally derived from adult require-
mentsonthebasisofbodyweight,butaredetermined
according to age-specific, physiological conditions (II).
• The fluid, nutrient and energy intake during the post-
partaladaptationandstabilisationphaseissubjectto
specific conditions, which necessitates a specific ap-
proach (II).
• In comparison to older paediatric patients or adults,
newborns and infants have an extremely low body
store of nutrients and in many respects immature
regulatory mechanisms, thus requiring an carefully
adapted intake to suit their specific requirements in
order to prevent imbalances (II).
• Inadequatesubstrateintakeinearlyinfancycancause
long-term detrimental effects in terms of metabolic
programming of the risk of illness in later life (II).
Physiological principles
The body water content is age-related and diminishes
from approx. 90% in a premature infant born after 24
weeks gestation to below 70% in a 12 month old infant
[2], [3].
Thefluidvolumeperkgbodyweightishigherinnewborns
thaninolderpatients[4].Contributingfactorsforthisare
renal immaturity (diminished ability to concentrate urine
resulting in increased urine volume) [5], higher energy
expenditure,greaterbodysurfaceareacomparedtobody
volumeandepidermisimmaturityresultinginhighinsens-
ible perspiration [6]. The regulatory mechanisms in the
waterandelectrolytebalancearereducedincomparison
to adults due to renal immaturity. Alongside the dimin-
ished ability of the kidneys to concentrate urine [7], the
renalglomerularfiltrationrate,renaltubularreabsorption
andeliminationofH
+-ionsarealsolowerwhencompared
to those of older children [8], [9]. Based on body weight,
the energy and nutrient requirements of newborns are
higher than in older patients. This results from the in-
creased (metabolic) activity and growth [10] resulting in
increased nutrient substrate requirements [11], [12],
[13], [14].
Apartfromtheknownnutritionaleffectsofnutrition,there
is also increasing evidence of long-term changes in the
metabolismtriggeredbynutritioninearlychildhood(early
metabolic programming of early nutrition on health in
later life) [15], [16].
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intake of nutrients that has been carefully adapted to
suit their metabolic requirements to a far greater degree
than older paediatric patients or adults. It is never appro-
priate to convert intake recommendations from other
patient groups like adults on the basis of body weight
and to apply them to infants or toddlers without taking
into consideration the different physiological conditions.
Apart from age-related changes in nutritional require-
ments, adaptation processes after birth (to a greater ex-
tent in premature infants) pose a special challenge with
regard to the individual requirements for fluid and other
nutrientsubstrates.Thereisaday-to-dayincreaseinfluid
andenergyrequirementsduetotheadaptationofmetab-
olism and kidney functions as well as initial high perspir-
ation. Daily adjustments to parenteral nutrition are,
therefore, required over the first few days of a child’s life
[17]. This adaptation and stabilisation phase (5–7 days
after the birth) is followed by the phase of stable growth.
After the neonatal period, the hydration percentage in
the fat-free body mass changes only slightly and the
percentage of body water content is mainly determined
by the percentage of fat in the body mass.
Indications for parenteral nutrition
Neonatal patients
• All premature infants <35 weeks of pregnancy and
most ill term infants require full or partial PN whilst
enteral nutrition is gradually introduced (IV).
• The percentage of PN should be reduced as quickly
as possible by the introduction of enteral nutrition
(partial PN) and finally be replaced completely by en-
teral nutrition in order to minimise any side-effects
from exposure to PN (II).
Commentary
There are a variety of reasons why premature infants
(<35 weeks gestation) and seriously ill full-term infants
maybeunabletoreceiveadequateenteralnutritionafter
birth,suchasgastrointestinaltractimmaturitywiththreat
of developing necrotising enterocolitis, muscular and
neurological immaturity, illnesses etc., and, hence, will
require immediate PN in most cases.
Thechoiceofnutritionadministered(oral,enteral,partial
PN or total PN) should be made on an individual basis
accordingtomedicalindicationandbasedontheprinciple
ofsuchnutritionbeing“asnon-invasiveaspossible”.This
processpromoteslowcomplicationrates[18],[19],[20],
[21] and is the reason why the highest possible percent-
ageofnutritionshouldbeadministeredorally,orenterally
wherever possible. If this is not possible, (partial) paren-
teral nutrition should be used to supplement the enteral
intake to provide adequate nutrition [22].
Premature infants are born with low food reserves (low
subcutaneous fatty tissue, low glycogen reserves in the
liver) in comparison to full-term newborns. There is spe-
cific risk of hypoglycaemia in connection with their high
nutrientrequirements.Prematureinfants<35fullweeks
of pregnancy should therefore be prophylactically
(re)introduced to solid food whilst administering (partial)
PN.The“optimumsupply”withvariousdifferentnutrition-
alcomponentsinprematureandillnewbornsisstillbeing
discussed. Principally it makes sense to differentiate
between the recommendations for the adaptation and
stabilisation phase and the recommendations for the
phaseofstablegrowth,duetodifferingnutritionalrequire-
ments.
Published recommendations (e.g. [11], [15], [23], [24],
[25], [26]) do not always take into consideration the
specific conditions of the adaptation and stabilisation
phase after birth (5–7 days after birth), which precede
the phase of stable growth.
Thismeansthatthestuntedgrowthoccurringduringthat
phase (compared to intrauterine percentiles) is often not
regained by the pregnancy due date [27]. There are dis-
cussions about this target stating that the majority of
eutrophic premature infants should have once again at-
tained their birth percentile by the pregnancy due date.
Thistargetseemsnecessary,becausegrowthretardation
could be a risk factor for long-term neurological develop-
ment [27], [28], [29]. The potential long-term risks of
growth retardation and the side-effects of increased
substrate intake in the newborn period have to be
weighed up as there is no evidence-based data on long-
termdevelopmentwhenconsideringthedifferentgrowth
ratesofprematureinfants.Theidealtargetforpremature
infants is usually seen as growth corresponding with in-
trauterine growth percentiles. It is, therefore, necessary
to adapt the nutrient supply to the respective needs of
the individual premature infant. This is also the case in
the phase of continual growth (see below), where the
target is not only to attain a positive nitrogen balance, as
in the adaptation and stabilisation phase, but also to
promote catch-up growth wherever possible right up to
the birth percentile.
Older children and teenagers
• Iftheenergyandnutrientdemandsofapatientcannot
be met through enteral nutrition during pre-school or
schoolage,thenpartialortotalPNistobeconsidered
within 7 days at the latest in dependance on the nutri-
tional state and clinical conditions (C).
Commentary
The beginning of (partial) parenteral nutrition in patients
abovetheperiodofinfancyshouldbespecifictotheindi-
vidual circumstances, age and illness of the child or
teenager. In contrast to infants, a period of inadequate
nutrition and depletion of the body’s store can be toler-
atedinpre-schoolandschoolchildrenwithpositivenutri-
tional status for up to seven days subject to their clinical
conditions.
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Energy requirements
Energy requirements are age-related (see Table 1) and
influenced by illness and therapy. Tables can provide
sufficient help in typical clinical situations providing a
roughapproachtocalculatingtheestimatedrequirements
of individual patients, with the appropriate additions and
deductions (e.g. in cases of pyrexia/respiratory therapy).
The estimate should account for the fact that all details
arebasedondatatakenfromhealthypatients.Individual
circumstances (e.g. reduced physical activity in case of
bed rest, infections, inflammatory processes, energy
losses from the stomata etc.) result in differences
between the actual energy requirements and the calcu-
lated (estimated) energy requirements.
Table 1: Benchmark for overall parenteral energy intake (incl.
amino acids) in stable patients [1]
The actual requirements of the treated patient can be
narrowed down further (e.g. weight chart) by means of
monitoring measures (cf. chapter “Complications and
monitoring”(http://www.egms.de/en/gms/2009-7/000
076.shtml)).
If the desired therapy effect (e.g. percentile parallel
growth)isnotattainedwiththeestimatedenergyrequire-
mentsandmonitoringoffersnosolidreferencesregarding
an adequate energy intake, then various formulas can
behelpfulwhencalculatingtheevaluation.Theequations
(WHO 1985, Schofield 1985, and Harris-Benedict 1919
[30], [31], [32]) have, however, also been established
forhealthychildrenandhavetobecorrectedforindividual
patients as specified in the figures published in tables.
Measuring the energy expenditure is rarely carried out
routinely during daily clinical routines and is indicated, if,
despite estimation aids and monitoring, there are still
doubts regarding an adequate energy intake.
We refer to the “Guidelines on Paediatric Parenteral Nu-
trition” of ESPGHAN and ESPEN for a more detailed
overview of aspects regarding the energy requirements
of children of various age groups and in case of varying
clinical pictures [1].
Carbohydrate requirements
• The endogenous glucose production varies from ap-
prox. 2 mg/kg/min (3 g/kg/day) in adults to approx.
8 mg/kg/min (11.5 g/kg/day) glucose in premature
infants (II).
• The maximum glucose oxidation is approx. 7
mg/kg/min (10 g/kg/day) in premature infants, and
approx. 12 mg/kg/min (18 g/kg/day) in full-term in-
fants and infants (II–III).
• In full-term infants and children up to two, the glucose
intake should usually not exceed approx. 12 mg/kg
and min (18 g/kg and day) (C).
• The glucose intake should also be adapted to the age
and/or clinical situation (e.g. malnutrition, acute ill-
ness, drug administration) (C).
• An excessively high carbohydrate intake can result in
net lipogenesis with hepatic fat deposition and stea-
tosis of the liver (II–III).
Commentary
Glucose is the sugar used for PN and usually contributes
substantially to osmolarity in the PN solution. The osmol-
arity of a glucose solution rises significantly with increas-
ing concentration from 255 mosm/l in a 5% glucose
solution to 1020 mosm/l in a 20% glucose solution.
Based on experience, glucose concentrations of up to
12.5% are well tolerated through a peripheral vein can-
nulaaslongasnootherosmolarity-increasingagentsare
added.
Glucose can be directly metabolised by the central
nervous system. The endogenous glucose production
varies from approx. 2 mg/kg/min (3 g/kg/day) in adults
to approx. 8 mg/kg/min (11.5 g/kg/day) glucose in pre-
mature infants [33], [34], [35], [36]. The maximum glu-
cose intake should not exceed the glucose oxidation rate
in PN. Maximum glucose oxidation is approx. 7
mg/kg/min(10g/kg/day)[37],[38]inprematureinfants
and approx. 12 mg/kg/min (18 g/kg/day) in full-term
newbornsandinfantsunderlong-termPN[39],[40],[41].
In critically ill children with burns, maximum glucose oxi-
dation of 5 mg/kg/min has been described [41].
Excessive glucose intake results in net lipogenesis and
subsequent fat deposition [42], [43]. Excessive intake
can lead to hepatic steatosis with an impairment of the
liver function [44], [45].
Special characteristics in neonatal
patients (hyper/hypoglycaemia)
• Higher incidence of hyperglycaemia with increasing
immaturity (lower gestational age) (II).
• Anearlystartofparenteralglucosetogetherwithamino
acids (2–3 g/kg and day) from the very first day on-
wards contributes to preventing hyperglycaemia in
premature infants. An early insulin therapy is also
promisingbutassociatedwithrisks.Furthercontrolled
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mendation (B).
Commentary
There are often fluctuations in blood sugar levels in pre-
mature infants during the adaptation and stabilisation
phasewhichcanbeinfluencedbylowsubstratereserves
(hypoglycaemia) or insulin resistance (hyperglycaemia)
[46], [47], [48]. Common definitions of hypo- or hyper-
glycaemia, respectively, are a blood glucose level of 50
mg/dl(2.75mmol/l)or150mg/dl(8.3mmol/l),respect-
ively, although these levels are not based on short and
long term outcome studies. The incidence of hyper-
glycaemia increases with diminishing gestational age
[49],[50].Anearlysupplyofintravenousinsulininhyper-
glycaemia has been proposed in order to more rapidly
attain the targeted energy intake and a positive nitrogen
balance [51], but this advantage should be weighed
against potential complications. There are no controlled
studies regarding the advantages and disadvantages of
an early insulin therapy in premature infants. It has also
been suggested that an added amino acid supply of 2–3
g/kgbodyweightanddayshouldbestartedfromthevery
first day to reduce hyperglycaemia during the adaptation
and stabilisation phase, since it may stimulate endogen-
ous insulin secretion and hence reduce the frequency
and extent of neonatal hyperglycaemia [52]. This ap-
proachshouldbeevaluatedfurtherincontrolledstudies.
Amino acid requirements
• Therequirementsforessentialaminoacidsarehigher
per kg body weight in infants, and particularly in pre-
mature infants, than in older children or adults (II).
Commentary
Crystalline amino acid solutions in concentrations of
3.5–15% (osmolarity 450–1450 mosmol/l) are used in
PN. Some specifics are to be taken into consideration
when using amino acid solutions in children compared
to adults due to the special amino acid metabolism and
growth-specific requirements.
The composition of amino acid solutions which are suit-
able for infants and toddlers, have to be adapted to the
demands of metabolic immaturity and requirements of
physical growth. Apart from the eight classic essential
amino acids (Phe, Thr, Val, Leu, Ile, Tyr, Ser, Met),
cysteine,tyrosine,histidine,taurine,glutamineandargin-
ine are regarded as essential or conditionally essential
especially in premature infants (see “Information on the
selection and production of amino acid solutions” in the
attachment).
Amino acid requirements for newborns
• Some amino acids regarded as non-essential in older
children and adults are regarded as conditionally es-
sential amino acids in newborns (II).
• Amino acid imbalances can result in toxic organ dam-
age and may be involved in the development of PN-
associated cholestasis (II).
• Ursodesoxycholic acid and the reduction of protein
intake have a positive effect on the development of
PN induced cholestasis in newborns (II).
Commentary
Theneedforessentialaminoacidsishigherinpremature
infants than in older children or adults [11].
Variousmetabolicpathwaysformetabolisingaminoacids
are immature in newborns (phenylalanine hydroxylase,
tyrosine-aminotransferase, cystathionase [53], [54]). As
a consequence amino acids regarded as non essential
in adults i.e. cysteine, tyrosine, histidine, taurine,
glutamineandarginine,become“conditionally”essential
amino acids in newborns [55], [56]. Other amino acids
like methionine quickly reach high levels because key
enzymes are immature. Amino acid imbalances develop
quicker in newborns than in adults or older children due
to the immaturity of the neonatal metabolism. Such im-
balances could have potential negative effects on organ
development [57].
The plasma amino acid levels in infants receiving paren-
teralnutritiondiffertothoseinbreast-fedinfantsdespite
extensive endeavours to create optimised amino acid
solutions for infants [58], [59], [60]. This is partly due to
the poor solubility or stability of various amino acids (e.g.
glutamine,tyrosine,cysteine)suchthatnotalladmixtures
can be used. The nitrogen balance is not significantly in-
fluenced by the diverse composition of amino acid solu-
tions [61], [62].
The maximum intake is basically influenced by two given
facts:
1. Physiological rate of protein synthesis subject to age:
According to data by Pohlandt et al. [63]and Micheli
[64] premature infants, who are physiologically in
approx. week 30 of pregnancy, have a maximum rate
of protein synthesis with protein requirements of ap-
prox.2.7g/kgbodyweight/day,whichreturnsto<2.0
g/kg body weight/day until week 40 of pregnancy. A
positive nitrogen balance can usually be attained in
premature infants with an amino acid intake of 2.5
g/kg body weight/day and 60–90 kcal/kg body
weight/day [65]. In individual cases an amino acid
intake of up to 3.5–4 g/kg body weight/day may be
necessary in order to achieve protein synthesis ac-
cording to the intrauterine ratio [64].
2. Urea and ammoniac concentrations in plasma:
The urea production rate is a sensitive measurement
foraminoacidutilisation.Monitoringplasmaconcen-
trations of functional proteins like, for example,
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provide information about the sufficient amino acid
supplyoftheliver.Itshouldbeconsideredthatstrong
insulin secretion due to high glucose intake guides
the n-flow to the muscles.
Nitrogen balance studies in premature infants receiving
parenteral nutrition show that approx. 380 mg (70%) are
retained from an intake of 530 mg nitrogen, similar to
theratiosfoundinenteralnutrition[66],[67].Aminoacid
imbalances in PN are also discussed as a factor for de-
veloping cholestasis in young infants (a frequent side ef-
fect of long-term PN; up to 50% of long-term ELBW-pre-
mature infants receiving parenteral nutrition develop
cholestasis [68]) [18], [69], [70].
Amino acid requirements in older
children and teenagers
Referencesaremadetotherecommendationsforenteral
intake of amino acids due to insufficient data regarding
the parenteral intake of amino acids in older children
[71] (see Table 2).
Table 2: Reference values for enteral protein intake according
tonewreferencevaluesfornutrientintakeinGermany,Austria
and Switzerland (DACH reference values) [71]
Lipid emulsions
• Lipid emulsions are an integral component of longer-
term PN in children (C).
• Lipid emulsion should usually amount to approx.
25–40%ofthenon-proteinenergyinpatientsreceiving
total parenteral nutrition (C).
• A glucose intake over 18 g/kg body weight and day
inducesnetlipogenesisininfantsandshouldgenerally
be avoided (B).
• To prevent a deficiency of essential fatty acids, a min-
imum intake of 0.25 g/kg body weight and day of li-
noleic acid is recommended in premature infants and
a minimum intake of 0.1 g/kg body weight and day li-
noleicacidisrecommendedinfull-termnewbornsand
children (C).
• In infants the parenteral lipid intake should usually
not exceed 3–4 g/kg body weight and day (0.13–0.17
g/kg body weight and h) (B) generally and in older
children it should not exceed 2–3 g/kg body weight
and day (0.08–0.13 g/kg body weight and h) (C).
• Premature infants, full-term newborns and infants
should usually receive lipid emulsions over 24 h (B)
or in case of cyclic infusion after the first few months
of life along with the residual PN (C).
• Triglycerideconcentrationsinserumorplasmashould
bespecifiedinpatientsreceivinglipidemulsionsespe-
cially if there is increased risk of hyperlipidemia (e.g.
high lipid intake, catabolism, sepsis, ELBW) (C).
• A reduction in lipid intake should be considered if
triglyceride concentrations in serum or plasma in
continuous infusions exceed 250 mg/dl (2.8 mmol/l)
in infants or 400 mg/dl (4.5 mmol/l) in older children
(C).
Commentary
Lipid emulsions are used in PN in paediatric patients as
they provide an energy source with low osmolarity and
high energy content per volume unit. In addition, they
also safeguard the essential fatty acid supply. The CO2
productionisloweredcomparedtoPNwithahighpropor-
tion of carbohydrates [72], [73], [74]. The nitrogen
metabolism can be improved by adding lipid emulsions
to PN [75], [76], [77].
Lipid oxidation depends on the overall energy intake and
consumption, intake of carbohydrates and triglycerides
andthecarbohydrate/lipidratio[72],[73].Lipidoxidation
decreases as the carbohydrate intake increases and is
replaced by lipid storage. Lipogenesis takes place in in-
fants with a carbohydrate intake of 18 g/kg/day and
above [39], [72]. In older children the level of carbo-
hydrate intake, above which net lipid deposition takes
place, is lower. Lipid oxidation reaches its maximum at
a parenteral lipid intake of 40% of non-protein energy
intake in neonates [74] or 50% in infants [72]. Generally
alipidintakeof25–40%ofnon-proteincaloriesisrecom-
mended.
A deficiency of essential fatty acids can be biochemically
shown in parenterally fed premature infants only after a
few days with continuous glucose but not lipid infusion
[78], [79], [80]. At least 0.25 g/kg body weight/day of li-
noleic acid should be administered to premature infants
in order to prevent a deficiency of essential fatty acids
[80], [81]. An intake of 0.1g/kg body weight/day is prob-
ably sufficient in full-term infants and older children. The
different linoleic acid content in varying lipid emulsions
has to be taken into consideration in the calculation for
lipid intake. It is difficult to define the minimum require-
mentsofalphalinolenicacid.Themajorityofdataonthis
subject has been gained from animal experiments [82].
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acid deficiency [83]. All lipid emulsions used in Germany
contain alpha linolenic acid.
It is also difficult to define the upper limit for lipid intake.
Inprematureinfantsanintakeof3g/kgbodyweight/day
is well tolerated as a continuous infusion according to
theconcentrationofplasmatriglyceridesandcholesterol
and also the ratio of non-esterified fatty acids/albumin
[84], [85], [86]. In premature infants it may be desirable
toachievealipidintakesurpassingtheoxidationcapacity
inordertoattainweightgainandlipiddeposition.Caution
is,however,recommendedinprematureinfantsweighing
less than 1000 g as tolerance to intravenous lipid emul-
sions may be more limited [87].
Maximum lipid oxidation of 4 g/kg body weight/day is
attained in full-term infants with a glucose intake below
18 g/kg per day [73], [75].
It is important to monitor plasma triglycerides because
lipid utilisation varies depending on age, the severity of
the illness and various other factors.
An increase in the concentration of plasma triglycerides
is to be expected if the infusion speed of the lipid emul-
sionsexceedsthespeedofhydrolosisofthetriglycerides.
In premature infants the gradual increase in lipid intake
compared to immediate administration of the target
amount did not result in raised lipid tolerance [88]. If a
gradual increase of 0.5 to 1 g/kg per day is carried out,
this can serve the purpose of monitoring with measure-
ments of plasma triglycerides concentrations.
Inprematureinfantstoleranceofalipidinfusionisraised
by continuous versus intermittent administration [84],
[86], [88]. In stable patients intermittent administration
can also be carried out within the framework of cyclic
home PN.
The speed of triglyceride hydrolysis depends on lipopro-
teinlipaseactivity.Theactivityofthepostheparinlipopro-
tein lipase can be raised by administering heparin but
this does not increase lipid utilisation [89], [90]. Raised
lipoprotein lipase activity results in increased non-esteri-
fied fatty acids, which are not necessarily metabolised at
the same speed [90], [91].
Lipid supply may result in enhanced lipid peroxidation
and the formation of free radicals [92], [93], [94]. An in-
creasedlipidutilisationbyreducingthecarbohydrate/lipid
ratio, at a constant lipid intake and therefore reduced
energy intake, results in a reduction of lipid peroxidation
and free radical formation [92]. PN should be supple-
mented with multi-vitamin preparations including both
vitamin C and vitamin E (alpha-tocopherol) which have
anti-oxidative effects [95], [96], [97].
PNwith20%lipidemulsionsresultsinmorephysiological
phospholipid and cholesterol levels, due to its low phos-
pholipid content compared with PN containing classic
10% lipid emulsions [98]. At the same time there is,
however,alowerproportionoflong-chainpolyunsaturated
fatty acids (LC-PUFA) contributed by the phospholipid
emulsifier. LC-PUFAs are “conditionally” essential for
premature infants. Deficiency could result in malforma-
tionsoftheretinaandcentralnervoussystem[99],[100].
Vitamin requirements
No age differentiation is indicated in literature due to the
limited data situation.
Neonatal patients, older children and
teenagers
• Vitamin supplementation should be given during par-
enteral nutrition (C).
• The vitamin requirements of premature infants and
newborns (excluding Vitamin D and K) as well as in
infants and children have not been extensively exam-
ined (IV).
• No parenteral vitamin supplement available on the
German market meets the current recommendations
for premature infants (IV).
• Vitamin preparations should, if possible, be admin-
istered together with the lipid emulsion (C).
• Prematureandillfull-terminfantsshouldbegiventheir
firsttwodosesofVitaminKsubcutaneously/intramus-
cularly or intravenously (II).
• An oral intake of 1000 IU Vitamin D/day is adequate
in extremely premature infants (II).
Commentary
The optimum time to begin vitamin supplementation in
newborns and premature infants is not clear. It should
be taken into consideration, that water soluble vitamins,
with the exception of Vitamin B12, are inadequately
stored. Insufficient thiamine intake can result in severe
lactic acidosis within only a few days in children on PN
[101]. It is, therefore, recommended that vitamin substi-
tution is started early with PN.
Vitamin intake should be administered daily. All clinical
studieshavebeencarriedoutwithcommerciallyavailable
vitamin preparations, therefore existing intake recom-
mendations [11], [23], [102] are based on the compos-
ition of available preparations. At this time there is no
commercially produced vitamin supplement available on
the market, which completely meets the current intake
recommendationsforprematureinfantsasasupplement
for long-term PN.
In the practical administration of PN it should be con-
sidered that vitamins can be degraded by oxygen, light
and heat. Degradation reactions can be accelerated by
catalytically active trace elements like copper and iron.
Fat-solublevitaminscanbeadsorbedonspecificsynthetic
materials (infusion needles) in rare cases. Thus, the ad-
ministereddoseisuncontrolledandsignificantlyreduced
[103]. In Europe, combined preparations are available
which, by dissolving the vitamins in a lipid emulsion, re-
duce absorption on plastic. Furthermore, the formation
of peroxides in lipid emulsions can be reduced by adding
multi-vitamin preparations [104]. Vitamin preparations
should, if possible, be administered together with the
lipid emulsion. The clinical impact of free radicals, which
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exposed to light, is being currently discussed. They can
result in an increase in peroxide excretion in urine of
newborns [105]. Feed lines with light protection should
be used when administering parenteral solutions with
vitamins until the clinical significance of these results
has been determined [106].
Vitamin D rickets prophylaxis: Oral vitamin D prophylaxis
with 1000 IU Vitamin D/day per os from day seven of life
is sufficient as a prophylaxis in extremely premature in-
fants [107].
Vitamin K prophylaxis: Premature infants (<week 35 of
pregnancy) and ill full-term infants should receive their
first two doses of Vitamin K prophylaxis intramuscularly,
subcutaneously or intravenously due to the unclear re-
sorption from the gastrointestinal tract [108], [109]. The
dose of intravenous Vitamin K prophylaxis is still being
discussedatpresent.VitaminKlevelsafteroneadminis-
tration of 1 mg Vit K intramuscularly on the first day of
life were higher in premature infants than in full-term in-
fants [110].
Detailed specifications can be found in the “Guidelines
on Paediatric Parenteral Nutrition” from ESPGHAN and
ESPEN [1].
Trace element requirements
Noagedifferentiationisindicatedinliteratureonaccount
of the limited data situation.
Neonatal patients, older children and
teenagers
• Theoptimumtimetobeginwithtraceelementsupple-
mentation in premature infants <1500 g birth weight
is not clear. We recommend beginning supplementa-
tion to coincide with an increase in body weight (5
th
day of life) (C).
• The trace element requirements of premature infants
and newborns as well as children have not undergone
extensive testing (IV).
• A parenteral trace element supplement, which meets
the current intake recommendations, is not available
on the German market (II).
• Trace elements should be supplemented in long-term
PN (C).
• Zinc deficiency has to be excluded in infants and chil-
drenwithunclear,poordevelopment(especiallylinear
growth) and/or skin efflorescences (typically on acra,
mechanically burdened parts of the body or in the
nappy region) or diarrhoea (II).
Commentary
Trace element requirements and optimum time to begin
supplementation in premature and full-term infants, as
wellasinfantsandchildren,arenotcompletelyclear.The
enteralabsorptionoftraceelementsinpartial-parenteral
nutrition mainly depends on the existing compound and
the composition of the nutrition [111] such that it is ex-
tremely difficult to evaluate the remaining parenteral
needs. Requirements for some trace elements have at
least been narrowed down by controlled studies [102],
[111], [112], [113], [114]. There is no trace element
supplement for long-term PN which meets the current
recommendations[102].Inlong-termPN(>7days),where
enteral nutrition provides less than 50% of the energy
intake, we recommend administering trace element
supplements according to manufacturer instructions.
Prematureandillfull-terminfantshaveanincreasedrisk
of developing a trace element deficiency. Premature in-
fants are born with lower trace element stores as the
laying down of these stores occurs during the last tri-
mester of the pregnancy. Rapid growth at unidentified
requirement levels and variable resorption are further
risk factors contributing to the development of a trace
element deficiency in premature infants [115]. In ill full-
term infants the requirements and intake vary according
to the basic illness. The optimum time to begin supple-
mentation is disputed.
Zinc: Zinc deficiency should be considered in newborns
where the reason for unclear, poor development (espe-
cially linear growth) and/or skin efflorescences (acra,
mechanically burdened parts of the body) are not clear
[116], [117]. A multitude of case studies have been
published on zinc deficiency in neonates [116]. Rare
genetically-relatedtraceelementmetabolicdisordersare
also to be considered in the case of unclear clinical
symptoms [117].
Other supplements
• There is no documentation indicating a benefit from
parenteral supplementation of glutamine or arginine
in children (C).
• Carnitine supplementation should be considered in
individualcasesinprematureandnewborninfantson
PE (B).
Commentary
Tests on arginine supplementation [118] in adult inten-
sive care patients as well as some studies on enteral or
parenteral glutamine administration in newborns show
potentialpositiveeffects[119],[120](II),althoughthese
are controversially discussed. There is no evidence from
meta analyses to document the benefit of the parenteral
supplementation of glutamine or arginine in premature
and newborn infants [121].
VitaminAisnecessaryforphysiologicallunggrowth(lung
epithelialcells).Ameta-analysis,whichisbasedonseven
randomised,controlledstudies,documentstheeffective-
ness of a supranutritive Vitamin A supplementation on
reducing oxygen requirements and improving survival at
onemonthofageinprematureinfantswithabirthweight
<1000 g. There is a tendency towards lower values re-
gardingtheincidenceofretinopathyinprematureinfants
[122], [123] (I). The authors of the systematic analysis
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out further studies on the effects of intravenous Vitamin
A supplementation.
Carnitineisnecessaryforthetransportationoflong-chain
fattyacidsviathemitochondrialmembraneanditsoxida-
tive metabolism. Carnitine is found in breast milk and
baby foods, but is not usually added to conventional PN.
Lowcarnitinelevelshavebeenmeasuredinbodytissues
inprematureinfantsonPN[124].Theclinicalsignificance
of this has not been determined. An impairment in fatty
acid oxidation is only to be anticipated where a massive
drop in serum carnitine concentrations occurs. For the
metabolic availability of carnitine its free nonesterified
percentage, is essential. The availability of free carnitine
is reflected in the concentration and the acyl-carnit-
ine/free carnitine (AC/FC) ratio. This ratio is in dynamic
equilibriumwiththeintramitochondrialacyl-CoA/freeCoA
ratio.LowerintramitochondrialCoA-availabilityisassumed
with an AC/FC ratio >0.4 (>0.7 when fasting) Carnitine
supplementationresultsinareleaseofintramitochondrial
CoAandshouldbeconsideredincaseofanexplicitAC/FC
ratio. A meta analysis (based on 14 randomised, con-
trolled studies) showed there to be no effect of carnitine
supplementationonthemetabolismoflipids,lipogenesis
or weight gain [125].
Practical procedure
Short, medium and long-term (partial)
parenteral nutrition
• The utilisation of an adapted glucose/electrolyte
solution (usually 10% glucose) with potassium and
sodium supplementation in short-term (<48 h) intra-
venous intake is recommended in well-nourished tod-
dlers and school children without specific metabolic
or nutritional risks (IV).
• An adapted glucose/electrolyte solution (usually 10%
glucose)withtherequiredsupplementationofsodium,
potassium,aminoacids,lipidsandvitaminsshouldbe
administered in medium-term PN (>2–7 days) (IV).
• An additionnal supplementation of magnesium, phos-
phate, and trace elements (where enteral nutritional
provides 50% of the energy intake or less) should be
administered in long-term PN (>7 days) (IV).
Commentary
Ifintravenousintakeisrequiredinwell-nourishedtoddlers
and school children without specific metabolic or nutri-
tionalrisks,thefollowingsituationsshouldbeconsidered
when anticipating duration:
I: short-term parenteral intake for less than 48 h.
II: medium-term parenteral nutrition for 2 to 7 days.
III: long-term PN for >7 days.
• Itmakessensetodifferentiatebetweenshort,medium
and long-term parenteral intake, because the proced-
ure varies according to the duration of PN
• The utilisation of an adapted glucose/electrolyte
solution (usually 10% glucose) with potassium and
sodium supplementation in short-term (<48 h) intra-
venous intake is recommended in well-nourished tod-
dlers and school children without specific metabolic
or nutritional risks (IV).
• An adapted glucose/electrolyte solution (usually 10%
glucose)withtherequiredsupplementationofsodium,
potassium,aminoacids,lipidsandvitaminsshouldbe
administered in medium-term PN (>2–7 days) (IV).
• An additional supplementation of magnesium, phos-
phate, and trace elements (where enteral nutritional
provides 50% of the energy intake or less) should be
administered in long-term PN (>7 days).
Newborns and infants
• There should be a written concept on the provision of
PN in order to minimise errors (C).
• Newborns can be divided up into the following groups
with regard to their nutrient requirements and PN-
support in order to minimise errors:
premature infants <1500 g, •
premature infants >1500 g, •
ill full-term infants (C). •
• The actual amount of PN administered must be calcu-
lated(notestimated)inneonates(avoidroundingerror)
(C).
• The use of PN standard solutions can reduce the the
risk of errors.
Commentary
Due to the heterogeneity in pathophysiology and the dif-
fering maturity of patients it may be necessary to vary
proceduresduringtheneonatalperiod(e.g.fluidvolumes,
electrolyte substitution etc.). Classification according to,
for example, birth weight is recommended for the calcu-
lation of PN in neonates:
premature infants <1500 g, •
premature infants >1500 g, and •
ill full-term infants. •
This differentiation makes sense with regards to vari-
ations in the administration of different nutrients. The
describedprotocolcanresultintheproceduresin(partial)
parenteral nutrition being structured during the daily
clinical routine and errors minimised.
A standardised questionnaire or electronic programme,
which takes into account partial parenteral nutrition and
enteral nutrition (see Table 3 for an example of a proced-
ure questionnaire), should be used for prescribing PN to
neonates.
The prescription of nutrition for neonates must be calcu-
lated and not estimated in order to ensure the nutrient
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Table 3: Example of a procedure questionnaire in premature and ill full-term infants
intakeinneonatesandinfantsisadaptedtotheirspecific
needs.
PN in premature infants and newborns
PN in the adaptation and stabilisation phase
after birth
• There is no evidence-based data on the scale of post-
partal weight loss required during the adaptation and
stabilisation phase for long-term development (IV).
• Amino acid and lipid supply should begin on the first
day of life (B).
• The fluid intake in premature infants <1500 g should
only replace the estimated losses in the first days of
life(mainlyperspiratioinsensibilis).Electrolytesupple-
mentation is often not necessary (B).
• The incidence of hyperkaliaemia can be lowered by
supplementing PN with 1 g amino acids from the first
day of life in premature infants <1500 g (II).
• Themaximumparenteralintakeofaminoacidsshould
be between 2 and max. 4 g/kg body weight per day in
premature infants and newborns (B).
• Max. lipid intake should not exceed 3–4 g/kg body
weightperdayinprematureinfantsandnewborns(B).
• Restricted fluid management with limited supply of
sodium chloride results in a reduction in the amount
of days with respiratory aids or respiratory therapy (II).
• Theearlyenteral(re)establishingofsolidfoods(within
<4 days after the birth) in premature infants lowers
the incidence nosocomial infections, the duration of
PN and the frequency in the utilisation of central ven-
ous catheters (I).
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In premature infants and full-term newborns there is a
period of adaptation and maturation which occurs in the
firstsevendaysafterbirth(see“Physiologicalprinciples”
above) which requires daily adjustments in the nutrient
intake of ill full-term and premature infants. There is
surprisingly little evidence-based data on physiology and
nutrient requirements for this stage of life (optimum
weight loss, optimum time to begin amino acid and lipid
supply). Lipid (0.5–1 g/kg body weight/day) and amino
acid intake (0.5–1 g/kg body weight/day) should begin
on the first day of life [126], and a stepwise increase in
aminoacidintaketomax.2–3(–4)g/kgbodyweight/day
and lipid intake to 3–4 g/kg body weight/day is widely
practised and results in more rapid achievement of a
positive nitrogen balance [52], [127]. Questions remain
with regard to extremely small premature infants with a
birth wieght <800 g with regard to potential adverse ef-
fects of early intravenous lipid intake on the first day of
life[128].Arestrictedfluidvolumeimprovestheoutcome
of neonates considerably by lowering the “perspiratio in-
sensibilis” [129]. In premature infants a restrictive “dry”
fluidmanagementwithsodiumchloriderestrictionseems
to have a favourable effect on the duration of respiratory
aids / respiratory therapy [130], [131], [132]. Only the
losses should be replaced in the first days of life in pre-
mature infants under 1500 g birth weight [17]. The inci-
dence of hyperkaliaemia can be lowered by supplement-
ing1gaminoacidsfromthefirstdayoflifeinthispatient
group. The early (re)establishing of enteral nutrition(<4
daysafterbirth)lowerstheincidenceofnosocomialinfec-
tions, the duration of (partial) parenteral nutrition and
the utilisation of central venous catheters compared to
later (re)establishing [133], [134].
PN in premature infants and newborns in the
phase of continual growth
• Parenteral nutrition should be the exception in
neonatal patients during the phase of continuous
growth. If necessary, treatable reasons for delayed
enteral (re)establishing of nutrition should be ascer-
tained (C).
• The energy requirement shows great intraindividual
and interintervidual variability (II).
• The energy intake can be adapted to the weight gain,
whereby weight development should aim to be close
to the intrauterine growth curve (C).
Commentary
The enteral (re)establishing of nutrition is usually com-
pleted in the first week of the continual growth phase
(about the 2
nd week of life) in premature infants and sick
full-term infants. If PN is also required during this phase,
treatable reasons for delayed enteral (re)establishing of
nutritionshouldbeascertained.Theenergyrequirements
show great variability in this stage of life. They can be
estimated according to weight development compared
to intrauterine growth curves (if other reasons for growth
not following percentiles have been excluded, it should
be assumed that a too low energy intake will result in a
decline and a too high energy intake will result in gains
compared to intrauterine percentiles). The necessary
energy to build up 1 g body tissue varies with the lipid
content of the newly formed tissue (20–40%) but aver-
ages at approx. 5 kcal/g. The proportion of the newly
formedfattytissueisinfluencedbythenutritionalregime.
It should be considered with lesser fatty tissue built up,
the energy required for growth is lower [135].
Methods of access
• Peripheral vein cannulae have a lower complication
rate compared to central access points and should be
used in infants whenever possible (II).
• A routine heparin supply to prevent thrombosis or to
proling central venous catheter survival time has no
provenbenefitininfantsandisnotrecommended(Ib).
Commentary
Peripheralcommercialveincannulae(PCVC)havealower
complication rate in infants (infection, thrombosis) than
central venous catheters (CVC) [20]. Peripheral commer-
cial vein cannulae (PCVC) can be used in partial or total
parenteralnutritioniftheosmolarityandstateoftheveins
allow for this (risk of paravasatation/skin necrosis!).
Long-term total parenteral nutrition often cannot be ap-
pliedsafelyinolderchildrenorteenagerswithoutcentral
venous catheters (CVC) due to the osmolarity. An individ-
ual decision is required on the choice of access while
taking into consideration the underlying illness, therapy,
osmolarity of the nutritional solution used or drugs and
the expected duration.
Two meta-analyses showed no positive effect of heparin
supply on central venous catheter lifetime or the forma-
tion of thromboses in neonates with percutanous central
venous catheters [136], [137].
Use of standardised or individually
tailored PN solutions
• After requirements have been calculated, standard
solutions (e.g. produced by the hospital pharmacy),
which are adapted to suit the specific nutrient needs
of the respective age group, can be administered in
short-term PN (B).
Commentary
Using ready-made standard solutions requires fewer
personnelandallowsforlessriskregardingdosageerrors
or microbial contamination. Individually mixed infusions
can be adapted to individual characteristics. Standard
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PN provision
A standardised procedure should be followed and the
individual steps systematically documented in order to
minimise errors. Computer programmes, which enable
the fast and exact calculation of enteral and parenteral
intake, are recommended (and in part commercially
available). The fluid, glucose and electrolyte intakes and
additional intakes with drugs can be calculated.
The following aspects should be considered: Estimation
of the required duration of PN, enteral nutrition, fluid in-
take, protein and lipid intake, parenteral vs enteral/oral
intakes, electrolyte/vitamin and trace element supply,
concentration of the glucose solution, infusion speed,
monitoring, and validation (see Table 3 “Example of a
procedure questionnaire”).
Neonatal patients
A practical example is shown in Table 4, which illustrates
the (re)establishing of enteral food in newborns during
the adaptation and stabilisation phase.
Measures to reduce side-effects of
PN
• Proceduresshouldbestandardisedwhereverpossible
in order to minimise errors in the provision or prepar-
ation of partial (PPN) or total PN (TPN).
• Minimum enteral nutrition minimises the time until
(re)establishing of total enteral nutrition and LOS
(Length of Hospital Stay) (I).
• Non-nutritive sucking during PN reduces LOS (I).
• There is a specific risk of developing osteopenia due
to the rapid bone growth in premature and full-term
infants (III). Osteopenia prophylaxis should be started
enterally once the (re)establishing of enteral nutrition
has been completed without complications (C).
• In order to determine appropriate Ca and P intakes,
the Ca and P excretion can be assesed in spot urine
samples (B).
• The optimum duration of Ca and P supply is unclear
(IV), but it appears reasonable to provide a Ca and P
supplyuptothecorrectedthirdmonthoflifeinprema-
ture infants with a birth weight <1500 g (C).
Commentary
Minimum enteral nutrition
Total PN reduces the functional and structural integrity
of the gastrointestinal mucosa, the secretion of
gastrointestinal hormones and the activity of mucosal
enzymes like lactase [139], resulting in an intolerance to
enteral nutrition and an extension of LOS (Length of
Hospital Stay). A meta-analysis of eight randomised
studies [134] investigated the effect of minimum enteral
nutrition (<25 kcal/kg body weight/day for >5 days) on
the development of food intolerance in at-risk premature
infants (<1500 g birth weight, <week 33 of gestation) in
comparison to total PN. The duration of (re)establishing
ofnutritionandLOSwassignificantlyreduced.Therewas
no effect on the incidence of necrotising enterocolitis.
Side-effects of minimal enteral nutrition cannot be defin-
itely excluded due to the inhomogeneity of the patients
included and their low number [134].
Non-nutritive sucking
A meta-analysis (based on 14 randomised, controlled
studies) documented a significant reduction in LOS
through non-nutritive sucking in premature infants. No
effects have been found on weight gain, energy intake,
oxygen saturation, total intestinal transit or heart rate
[140].
Osteopenia prophylaxis in premature infants
<1500 g
Due to their high growth rate, premature infants have
high calcium and phosphate requirements which cannot
be met through breast milk or infant formula. Therefore,
premature infants with a very low birth weight (<1500 g)
are particularly at risk of developing osteopenia. Os-
teopenia in premature infants is linked to an increased
incidence of fractures, prolonged respiratory therapy or
requirement for respiratory aids and the development of
adolichocephalus[141],[142].Prematureinfantsunder
1500gbirthweightshouldreceiveCa/Psupplementation
dependingontheirindividualrequirements.Theoptimum
duration of supplementation is unclear. We recommend
supplementationinprematureinfantswithabirthweight
<1500 g up to corrected third month of life. The Ca and
P excretion from spot urine specimens may be used to
adapt the Ca and P supply to requirements, which vary
according to growth [143], [144].
Monitoring
• Duetothelowbloodvolumeininfants,staffatfacilities
in which infants receive medium and long-term par-
enteralnutritionmusthaveaccesstoaspeciallabora-
tory with micromethods (IV).
• Carefulmonitoringofthefluidvolumemustbecarried
outinprematureinfantsduetotheirhighfluidvolume,
high body water content in comparison to older pa-
tients and immature regulatory mechanisms (IV).
• Dehydration in premature infants, with immature kid-
neys, leads to hyperchloraemia prior to the develop-
ment of acidosis as one of the first lab signs.
• The measurement of the specific weight or osmolarity
of urine can only be drawn upon in premature infants
and newborns in the first weeks of life when high
valuesaremeasured.Low(normal)valuescanbedue
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1
to low renal concentrating ability in premature infants
and newborns as a result of immature kidneys (II).
• Daily clinical tests, fluid balances, acid-base status,
electrolytes and blood sugar are required during the
initial phase of PN, depending on the maturity and ill-
ness of neonates, (C).
• In medium and long-term PN, routine clinical tests
should also be accompanied by the following: docu-
mentation of weight, length and head circumference
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evaluation of acid base status, blood sugar, electro-
lytes, haematocrit, urea, creatinine, at least one
transaminase,Y-GT,urineosmolarityorspecificweight
(alkaline phosphatase every two weeks) (C).
Commentary
Daily clinical tests, to include the monitoring of the fluid
balance, checks of the acid base status, electrolytes and
blood sugar, are usually required in the initial phase of
PN depending on the age and maturity of the children
andtheirunderlyingillness.Inmediumandlong-termPN,
routine clinical tests should also be accompanied by the
following: documentation of weight, length and head cir-
cumference development (in percentile questionnaires),
weekly evaluation of acid base status, blood sugar, elec-
trolytes, haematocrit, urea, creatinine, at least one
transaminase, Y-GT, urine osmolarity or specific weight
(alkaline phosphatase every two weeks).
Lipids
The concentration of plasma triglycerides at which un-
desirable effects occur is not known [145]. Average
triglyceride concentrations of 150 to 200 mg/dl and
above are often specified in infants fed with breast milk
or infant formula [86], [146]. Values of 250 mg/dl in
healthy infants are not unusual. In older children higher
concentrations of up to 300 and 400 mg/dl can also be
acceptable as the lipoprotein lipase doesn’t become
saturated until approx. 400 mg/dl [147]. When gradually
introduced, plasma triglycerides should be initially
checked on a weekly basis for every 1 g/kg lipid intake
increase and after reaching maximum intake levels.
Newborns
Monitoring the fluid balance in premature infants and
sick newborns is extremely important due to their high
fluid volume, high body water content in comparison to
olderpatientsandimmatureregulatorymechanisms(see
above). Monitoring must take the special physiological
features of neonates into consideration to be efficient:
• The measurement of the specific weight or osmolarity
of urine are only indicative in premature infants and
newborns in the first weeks of life when high values
are measured. Low (normal) values can be due to low
renal concentrating ability in premature infants and
newborns because of immature kidneys.
• The immaturity of the kidney in premature infants in
case of dehydration leads to hyperchloraemia prior to
the development of acidosis as one of the first lab-
chemical signs.
• Duetothelowbloodvolumeinneonates,staffatfacil-
ities in which neonates can receive medium and long-
termparenteralnutritionmusthaveaccesstoaspecial
laboratory with micro methods.
Attachment
Information on the selection and
production of amino acid solutions
• Several metabolic pathways involved in the synthesis
of amino acids are still immature in newborn and pre-
mature infants. As a result, some amino acids, which
areregardedasnon-essentialforadults,maybecome
conditionallyessential(e.g.cysteine,tyrosine,histidine,
taurine,andglutamine).Inaddition,individualplasma
amino acids reach clearly increased levels because
significant degradation enzymes are still immature.
Aminoacidimbalancesoccurmorerapidlyincompari-
son to adults (I).
Commentary
Increased phenylalanine concentrations are toxic for the
centralnervoussystemandcanresultinseriousdevelop-
mentaldisorders.Bothhepaticphenylalaninehydroxylase
activity and the enzymatic system of the metabolism of
tyrosine are still immature in premature infants. Prema-
ture infants (<week 30 of pregnancy) with high amino
acid intakes therefore have a tendency to develop hyper-
phenylalaninaemia and hypertyrosinaemia.
The enzyme activities in full-term infants result, however,
in a rapid amino acid metabolism, causing low
phenylalanine and tyrosine concentrations. Attempts are
madetoincreasethelowplasmatyrosineconcentrations
ininfantsreceivingparenteralnutritionbysupplementing
with N-acetyl tyrosine, which is more soluble. Newborns
and premature infants do still, however, have a reduced
deacetylation capacity such that tyrosine may not be
sufficientlyutilisedinthismoresolubleform[148],[149],
[150], [151].
There is an interaction between the branched-chain and
aromaticaminoacids:Leucinesupportsthephenylalanine
and tyrosine metabolism [152].
Methionine is a sulphurous, essential amino acid and is
regarded as the precursor to cysteine and taurine. Me-
thionine is the major methyl group donator in the hepatic
intermediarymetabolism.Itisconvertedtohomocysteine
throughdemethylation,whichremethylatestomethionine
when tetrahydrofolic acid is introduced or which is finally
converted to cysteine via a transsulfuration pathway
forming cystathionine.
Cysteine is a largely essential amino acid in both prema-
ture infants and full-term newborns due to its immature
cystathionase activity. Plasma cysteine concentration is
already a function of methionine intake in premature in-
fants. It is often observed that normal plasma cysteine
concentrations only occur if plasma methionine concen-
trations are raised. As a result cysteine supplementation
ofaminoacidsolutionsisrecommendedinyounginfants
[153], [154].
Supplementation with cysteine-HCl is not usually applied
because of its low solubility and risk of acidosis. The
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olised due to limited deacetylation and immature meta-
bolicratesinprematureinfants.Procysteine,apreliminary
stage of glutathione, has also been tested [155].
Taurine is formed through decarboxylation of cysteine
sulfinic acid, an enzyme stage that is still immature in
premature infants. The foetus accumulates approx.
50–60 µmol taurine/day during the last trimester of
pregnancy [156].
Taurine has many functions, not all of which are com-
pletely understood, although it is of importance to the
centralnervoussystem,retinaandgastrointestinaltract.
The proven relevance of the maturing of acoustically
evoked potentials points to the clinical significance of
taurine [157], [158]. Young infants on PN are, therefore,
dependent on exogenous taurine intake in order to
maintain plasma concentrations [157], [159].
Threonine:Theplasmathreonineconcentrationisdirectly
proportionaltotheintakeaswellasinverselyproportional
to the gestational age in PN for premature infants [160].
A toxicity of raised plasma threonine concentrations has
not yet been proven, although it is kown that concentra-
tion levels in the brain increase proportionally to plasma
concentrations.
Lysine: Of all amino acids the materno-foetal gradient is
most prominent in lysine. Plasma lysine concentrations
in the foetus are approx. four times higher than those of
the mother. Both lysine deficiency and surplus have
negative effects on growth, brain DNA concentration and
the dynamics of urea synthesis [161].
Leucine influences the speed of protein synthesis in the
muscles. The demand for branched-chain amino acids
is greater in premature infants than in full-term infants,
and thus they easily tolerate amino acid solutions with a
higher concentration of branched-chain amino acids.
Histidine: Of all essential amino acids, the plasma con-
centration of histidine is least influenced by the intake.
Histidineisthereforeregardedasaconditionallyessential
amino acid in young infants.
Arginine: The arginine concentration in an amino acid
solution contributes to preventing hyperammonaemia.
Prematureinfantswithasymptomatichyperammonaemia
showlowerplasmaconcentrationsofureacycleintermedi-
ates, which can be normalised by raising the arginine in-
take. Part of the arginine requirement can also be met
by ornithine, which is taken into consideration in some
amino acid solutions [162].
N-acetyl amino acids
• Based on recent data, it is assumed that N-acetyl
amino acids are only metabolised to a limited extent
in humans and therefore are only of limited signific-
ance as alternative amino acid sources in clinical nu-
trition (IV).
Commentary
Therearenodocumentedbenefitsofadditionallyadmin-
isteringN-acetylcysteineduetolimiteddeacetylationand
immature metabolic rates in premature infants.
Notes on differences between lipid
emulsions
• PE with a low phospholipid triglyceride ratio (e.g. in
20%lipidemulsions)resultsinlesselevatedphospho-
lipid and cholesterol levels (II).
• The use of lipid emulsions on the basis of soy bean
oil, an olive oil-soy bean oil mixture as well as a
coconut oil (MCT)-soy bean oil mixture have been
tested in paediatric patients and their use is well es-
tablished (I).
• None of these lipid emulsions have a documented
benefit regarding the attained clinical end points (C).
Commentary
Apart from the long established use of lipid emulsions
based on soy bean oil, a new emulsion based on an olive
oil and soy bean oil mixture has been available for some
time and studies with this new mixture have already
shown promising results in children, infants and prema-
ture infants [163], [164]. Postulated benefits of the olive
oil-based lipid emulsions are reduced lipid peroxidation,
lower PUFA intake and higher intake of antioxidative
substances. Currently data are insufficient to propose a
recommendation for olive oil-based emulsions [165].
Soybeanandoliveoil-basedlipidemulsionscontainlong
chain triglycerides. There are also lipid emulsions with
the equal proportions of LCT and MCT from coconut oil.
They contain less PUFA, and the MCT proportion is oxi-
dised more rapidly [166]. A further potential benefit is
that oxidation of MCT is less dependent on carnitine that
of LCT. The energy content of MCT per g fat is, however,
approx.16%lowerthanthatofLCT.Studiesinadultsand
children show a higher lipid oxidation, less influence on
the parameters of the liver function, improved leukocyte
functionandlessinfluenceonpulmonaryhaemodynamics
and the gas exchange than with LCT emulsions [167],
[168], [169], [170], [171]. There were no significant dif-
ferences in regard to the plasma lipids and fatty acids
[167], [172], [173], [174]. There is differing data con-
cerning a nitrogen-saving effect when administering a
MCT/LCTmixture.Onestudydescribesincreasednitrogen
retention [175], [176], while another study describes a
more unfavourable leucine metabolism than when on
LCT intake [177]. The current studies in children and
newborns [125], [167], [173], [178], [179] do not justify
any generally favoured utilisation of MCT/LCT emulsions
comparedtopureLCTemulsionsatpresent[165],[174].
The ratio between phospholipids (PL) and triglycerides
(TG)islowerin20%lipidemulsionsthaninstandard10%
lipid emulsions [180]. Lipid emulsions with a low PL/TG
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voured in PN [98], [125], [181], [182]. Higher amounts
of phospholipids impair the clearance of triglycerides
from the plasma, resulting in an increase in the plasma
triglyceride concentration and of cholesterol and phos-
pholipidsinLow-Density-Lipoproteins[98].Theemulsion
characteristics (dispersity, stability) and various incom-
patibilities are of great significance in the parenteral in-
take of lipids.
Notes
This article is part of the publication of the Guidelines on
Parenteral Nutrition from the German Society for Nutri-
tional Medicine (overview and corresponding address
under http://www.egms.de/en/gms/2009-7/000086.
shtml).
English version edited by Sabine Verwied-Jorky, Rashmi
Mittal and Berthold Koletzko, Univ. of Munich Medical
Centre, Munich, Germany.
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